HAVAH Therapeutics
- Company typePrivate
- Founded2019
- HeadquartersPalo Alto, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
HAVAH Therapeutics firmographics
Firmographics- Name
- HAVAH Therapeutics
- Legal name
- Havah Therapeutics Pty Ltd
- Website
- https://havahtx.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
HAVAH Therapeutics industry classification
Industry- Product category
- Breast Cancer Therapeutics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Breast Oncology (HLAKAFAJ)
Keywords
Where HAVAH Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Palo Alto
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
HAVAH Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Pharmaceutical Product Sales: Pre-revenue clinical stage biotech company. Once commercialized, the company will generate revenue through sales of its T+Ai hormonal implant therapy for breast cancer treatment and prevention. Target indications include DCIS, early-stage ER+ breast cancer, and prevention of hormonal refractory disease.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
HAVAH Therapeutics product offering
Product offeringCore offering
HAVAH Therapeutics is a clinical-stage biopharmaceutical company developing androgen-based hormonal therapies for breast disease. Its lead candidate HAV-088 is a first-in-class androgen receptor agonist delivered through a proprietary T+Ai subcutaneous extended-release pellet that combines testosterone and low-dose anastrozole to maintain intramammary DHT levels, supporting antiproliferative and anti-inflammatory cellular processes for treatment of DCIS, ER+ breast cancer, and prevention of hormonal refractory disease.
Product overview
HAVAH Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of androgen-based therapies for breast disease. The core technology is the T+Ai™ platform—a proprietary subcutaneous extended-release pellet combining testosterone with anastrozole. The lead product candidate, HAV-088, leverages this technology to deliver first-in-class androgen receptor agonist therapy for hormone receptor positive breast cancer and DCIS. The company has over 3,500 woman-years of clinical exposure across its programs. The product portfolio centers on 'endocrine steering'—targeted modulation of hormonal balance in breast tissue to achieve more nuanced hormonal regulation than traditional therapies. The T+Ai pellet provides precise delivery of testosterone for women with a unique PK profile that drives the hormonal milieu of the breast.
Differentiator
Problem solved
Functional benefit
Brands
- T+Ai: Combination treatment containing testosterone and anastrozole in a subcutaneous extended-release pellet therapy for breast cancer prevention and treatment.
Products and services
- HAV-088 First-in-class androgen receptor agonist delivered as a subcutaneous implant that combines testosterone and anastrozole for the treatment of hormone receptor positive breast cancer, specifically targeting DCIS and high-risk premenopausal women. The product leverages the proprietary T+Ai extended-release pellet technology to maintain breast tissue DHT levels, drive antiproliferative effects, and support anti-inflammatory cell function.
Quantifiable outcome
- Statistically significant reductions in mammographic breast density (MBD) and Background Parenchymal Enhancement (BPE), both known indicators of breast cancer risk
- +2 more outcomes
Companies that use HAVAH Therapeutics
Customer profileSegments2 records
Ideal customer profiles2 records
HAVAH Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
HAVAH Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Quantum Leap Healthcare Collaborative (QLHC)coreQLHC initiated the landmark RECAST DCIS Phase 2 platform trial evaluating alternative DCIS treatments. Havah Therapeutics is one of three investigational endocrine therapy arms being evaluated in this trial, which aims to revolutionize DCIS treatment and reduce unnecessary surgeries. The trial will enroll over 300 patients across 40 US sites.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
HAVAH Therapeutics competitors and assessment
Company assessmentDirect peers
- Quantum Leap Healthcare Collaborative: Direct partner running the RECAST DCIS Phase 2 platform trial in which HAV-088 is one of three investigational endocrine arms; highly relevant as the operational and clinical comparator environment for Havah's lead program.
- Atossa Therapeutics: Clinical-stage biotech developing therapeutics for breast cancer and breast health, including DCIS and hormonal therapies. Comparable as a small-cap US oncology company pursuing novel endocrine mechanisms in breast disease.
- Olema Oncology: Clinical-stage oncology company developing targeted endocrine therapies for ER+ breast cancer. Comparable in stage, mechanism focus (novel endocrine modulation), and target indication overlap with HAV-088.
- Context Therapeutics: Clinical-stage women's oncology company developing therapies for hormone-driven cancers including ER+ breast cancer. Comparable as a small-cap peer targeting hormonal mechanisms in breast cancer.
- Sermonix Pharmaceuticals: Privately held women's health oncology company focused on ER+ breast cancer therapies, including novel endocrine agents. Comparable in size, focus, and clinical-stage positioning to Havah.
Others
- Jasper Therapeutics: Public Nasdaq clinical-stage biotech led by Havah board director Ron Martell. Relevant as a comparable capital-markets-stage biotech with director-level overlap and similarity in fundraising profile.
- Ashvattha Therapeutics: Clinical-stage biotech where CEO Matt Brewer previously served as CBO and raised $65M. Comparable as a small clinical-stage biotech where the current leadership has direct execution experience.
Emerging players
- Dimerix: ASX-listed clinical-stage biotech also led by former Havah CEO Kathy Harrison. Comparable as an Australian-listed small-cap biotech transitioning through clinical development.
Broad incumbents
- Arvinas: Clinical-to-commercial stage oncology company with programs in ER+ breast cancer (vepdegestrant). Comparable as a breast cancer specialist with more advanced clinical stage and broader endocrine pipeline.
- Hologic: Large commercial medical device and diagnostics company in women's health/breast cancer (acquired Bolder Surgical, led by Havah's CFO previously). Comparable as a strategic acquirer and broad incumbent in breast cancer workflows.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
HAVAH Therapeutics social profiles
Digital presenceHAVAH Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
HAVAH Therapeutics leadership team
Management profileNumber of profiles
Profiles6 records
HAVAH Therapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HAVAH Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HAVAH Therapeutics
What does HAVAH Therapeutics do?
HAVAH Therapeutics is a clinical-stage biopharmaceutical company developing androgen-based hormonal therapies for breast disease. Its lead candidate HAV-088 is a first-in-class androgen receptor agonist delivered through a proprietary T+Ai subcutaneous extended-release pellet that combines testosterone and low-dose anastrozole to maintain intramammary DHT levels, supporting antiproliferative and anti-inflammatory cellular processes for treatment of DCIS, ER+ breast cancer, and prevention of hormonal refractory disease.
Is HAVAH Therapeutics a public or private company?
HAVAH Therapeutics is a private company. It is classified as unknown and is currently operating.
When was HAVAH Therapeutics founded?
HAVAH Therapeutics was founded in 2019. It employs 1 to 10 people.
Where is HAVAH Therapeutics based?
HAVAH Therapeutics is headquartered in Palo Alto, United States, in the North America region.
How does HAVAH Therapeutics make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are HAVAH Therapeutics's main competitors?
Direct peers on record are Quantum Leap Healthcare Collaborative, Atossa Therapeutics, Olema Oncology, Context Therapeutics and Sermonix Pharmaceuticals. Others are Jasper Therapeutics and Ashvattha Therapeutics. Dimerix is listed as an emerging player. Broad incumbents are Arvinas and Hologic.
Does HAVAH Therapeutics have an API?
No public API is recorded for HAVAH Therapeutics.
What industry is HAVAH Therapeutics in?
HAVAH Therapeutics's product category is Breast Cancer Therapeutics. Its primary akta.pro industry code is HLAKAFAJ, Breast Oncology. Its NAICS code is 325412 and its SIC code is 2834.